Poseida Licenses Janssen’s Centyrins to Develop CAR Therapies

News   Aug 12, 2015

 
Poseida Licenses Janssen’s Centyrins to Develop CAR Therapies
 
 
 

RELATED ARTICLES

CRISPR Screening Reveals Sickle Cell Disease Target

News

A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.

READ MORE

Modified Form of Botox Could Replace Opioids as Treatment for Chronic Pain

News

A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.

READ MORE

Broadly Acting Antibodies Found in Blood of Ebola Survivors

News

Scientists have discovered a set of powerful, broadly neutralizing antibodies in the blood of Ebola survivors. In animal studies, two of these antibodies provided substantial protection against disease caused by the three species known to cause fatal human illness.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy